FDA approves GSK Hibsago bepirovirsen as first antisense treatment for chronic hepatitis B
The FDA has approved GSK's Hibsago as the first antisense oligonucleotide treatment for chronic hepatitis B, offering eligible patients a new approach to sustained viral control.
Hibsago (bepirovirsen) is authorised alongside nucleos(t)ide analogue antiviral therapy for adults without cirrhosis who have received antiviral treatment for at least six months, have suppressed hepatitis B viral DNA and have HBsAg levels no higher than 3000 IU/mL.
The approval introduces a treatment with a different mechanism from conventional antivirals and offers the possibility of sustained viral control after treatment discontinuation for some eligible patients, although individual outcomes and follow-up requirements remain important.
Field | Content |
Article Type | Approvals |
Drug Name | Hibsago |
Generic Name | Bepirovirsen |
Company | GSK |
Regulatory Authority | U.S. Food and Drug Administration |
Regulatory Decision | New drug approval |
Approval Announcement Date | 20 October 2026 |
Indication | Chronic hepatitis B in eligible adults |
Patient Population | Adults without cirrhosis who have received nucleos(t)ide analogue antiviral therapy for at least six months, have suppressed HBV DNA and have HBsAg levels no higher than 3000 IU/mL |
Therapeutic Area | Infectious diseases; hepatology |
Drug Class | Antisense oligonucleotide |
Treatment Regimen | Used alongside nucleos(t)ide analogue antiviral therapy |
Prior Treatment Requirement | At least six months of antiviral treatment |
Viral Suppression Requirement | Suppressed hepatitis B viral DNA |
HBsAg Eligibility Threshold | No higher than 3000 IU/mL |
Cirrhosis Restriction | Adults without cirrhosis |
Approval Significance | First approved antisense oligonucleotide treatment for chronic hepatitis B |
Potential Treatment Benefit | Possibility of sustained viral control after stopping treatment for some eligible patients |
Clinical Evidence | Specific pivotal study results and efficacy percentages were not provided in the supplied summary |
Geography | United States |
What Happened | The FDA approved GSK's Hibsago bepirovirsen for eligible adults with chronic hepatitis B. |
Why It Matters | The approval introduces an antisense treatment approach for a chronic viral infection that commonly requires prolonged antiviral management. |
Potential Impact | Eligible patients may gain an additional treatment option with the potential for sustained viral control after therapy. |
Key Takeaway | Hibsago is a newly approved antisense treatment for selected adults with chronic hepatitis B, subject to defined antiviral treatment and laboratory eligibility requirements. |
What to Watch | US prescribing guidance, treatment availability, reimbursement, sustained treatment-response data and longer-term safety outcomes. |
Primary Source | U.S. Food and Drug Administration |
Primary Source URL | https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-chronic-hepatitis-b-treatment |
Relevant Date | 20 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments